Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN

Impact · against what's priced in

Cosmos Health secures a five-year contract to produce 385,000 units of CERTORUN and expands its infrastructure with a new ACG capsule production line. These developments provide predictable, high-margin revenue and increase the company's overall manufacturing capacity.

COSM+0.50: No priced-in read yet

Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN

What matters in this story

$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09%

Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN

What matters in this story

$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09%

How each ticker is affected

Track these names every morning.

Regeneron: 3 Key Takeaways for Long-Term Investors

AbbVie: 3 Key Takeaways for Long-Term Investors

Is AbbVie a Buy After Its Latest Earnings Report?

PolyNovo Limited (CALZF) Shareholder/Analyst Call Transcript

Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN

What matters in this story

Next reads from the same story arc

$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09%

Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN

What matters in this story

Next reads from the same story arc

$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09%

How each ticker is affected

Track these names every morning.

Regeneron: 3 Key Takeaways for Long-Term Investors

AbbVie: 3 Key Takeaways for Long-Term Investors

Is AbbVie a Buy After Its Latest Earnings Report?

PolyNovo Limited (CALZF) Shareholder/Analyst Call Transcript